Biological treatments for moderate-to-severe psoriasis: Indirect comparison

Journal of Clinical Pharmacy and Therapeutics

Volumn 38, Issue 2, 2013, Pages 121-130

  Galvan Banqueri M ^a   Marin Gil R ^b   Santos Ramos, B ^c   Bautista Paloma, F J ^c  

^a Andalusian Public Foundation for the Management of Health Research   (Spain)

^b Pharmacy and Health Benefits Andalusian Health Service   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

anti TNF ; effectiveness; indirect comparison; psoriasis; ustekinumab

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; RETINOID; RETINOL DERIVATIVE; STEROID; USTEKINUMAB; VITAMIN D DERIVATIVE; BIOLOGICAL FACTOR; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; CORTICOSTEROID THERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOADING DRUG DOSE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOTHERAPY; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; TOPICAL TREATMENT; ADULT; COMPARATIVE EFFECTIVENESS; COST BENEFIT ANALYSIS; DOUBLE BLIND PROCEDURE; FEMALE; MALE; METABOLISM; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); THERAPEUTIC EQUIVALENCE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL FACTORS; COMPARATIVE EFFECTIVENESS RESEARCH; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; THERAPEUTIC EQUIVALENCY;

EID: 84874976199     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12044     Document Type: Article

References (35)

1. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T,. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation Patient-Membership Survey. Arch Dermatol, 2001; 137: 280-284.
2. Schon MP, Boehncke W-H,. Psoriasis. N Engl J Med, 2005; 352: 1899-1912.
3. Ferrándiz C,. Nuevos tratamientos en la psoriasis. Med Clin, 2007; 129: 377-378.
4. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ,. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol, 2005; 141: 1537.
5. Faber EM, Nall ML,. The natural history of psoriasis in 5600 patients. Dermatologica, 1974; 148: 1.
6. Heydendael VMR, Spuls PI, Opmeer BC, et al,. Methotrexate vs. cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med, 2003; 349: 658-665.
7. Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, et al,. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol, 2005; 175: 2721-2729.
8. Nickoloff BJ, Stevens SR,. What have we learned in dermatology from the biologic therapies? J Am Acad Dermatol, 2006; 54: S143-S151.
9. McKenzie BS, Kastelein RA, Cua DJ,. Understanding the IL-23-IL-17 immune pathway. Trends Immunol, 2006; 27: 17-23.
10. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double blind, placebo-controlled trial (PHOENIX 1). The Lancet, 2008; 371: 1665-1674.
11. Papp KA, Langley RG, Lebwohl M, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double blind, placebo-controlled trial (PHOENIX 2). The Lancet, 2008; 371: 1675-1684.
12. Griffiths CE, Strober BE, van de Kerkhof P, et al,. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis (ACCEPT). N Engl J Med, 2010; 362: 118-128.
13. Summary of product Characteristics. European Medicines Agency. 2002. Available at: http://www.ema.europa.eu/ema/ (accessed 21 August 2012).
14. Lebwohl M, Yeilding N, Szapary P, et al,. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate-to-severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol, 2011; 63: 571-579.
15. Bucher HC, Guyatt GH, Griffith LE, Walter SD,. The results of direct and indirect treatment com-parisons in meta-analysis of randomized controlled trials. J Clin Epidemiol, 1997; 50: 683-691.
16. Wells GA, Sultan SA, Chen L, Khan M, Coyle D,. 2009. Indirect evidence: indirect treatment comparisons in meta-analysis. Available at: http:// www.cadth.ca/media/pdf/H0462-itc-tr-e.pdf (accessed 21 August 2012).
17. Saurat JH, Stingl G, Dubertret L, et al,. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs.placebo in patients with psoriasis (CHAMPION). Br J Dermatol, 2008; 158: 558-566.
18. Gottlieb AB, Matheson RT, Lowe N, et al,. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol, 2003; 139: 1627-1632.
19. van de Kerkhof PC, Segaert S, Lahfa M, et al,. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol, 2008; 159: 1177-1185.
20. Tyring S, Gottlieb A, Papp K, et al,. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet, 2006; 367: 29-35.
21. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al,. Etanercept as monotherapy in patients with psoriasis. N Engl J Med, 2003; 349: 2014-2022.
22. Schmitt J, Wozel G,. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology, 2005; 210: 194-199.
23. Finlay AY,. Current severe psoriasis and the Rule of Tens. Br J Dermatol, 2005; 152: 861-867.
24. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CEM, Nakanishi AM, et al,. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol, 2005; 152: 1304-1312.
25. Argimõn JM,. El intervalo de confianza: algo más que un valor de significaciõn estadística. Med Clin, 2002; 118: 382-384.
26. Delgado O, Puigventõs F, Pinteño M, Ventayol P,. Equivalencia Terapéutica: Concepto y niveles de evidencia. Med Clin, 2007; 129: 736-745.
27. Reich K, Burden AD, Eaton JN, Hawkins NS,. Efficacy of biologics in the treatment of moderate-to-severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol, 2012; 166: 179-188.
28. Gallego-Galisteo M, Villa-Rubio A, Alegre-del Rey E, Márquez- Fernández E, Ramos-Báez JJ,. Indirect comparison of biological treatments in refractory rheumatoid arthritis. J Clin Pharm Ther, 2012; 37: 301-307.
29. Tsai TF, Ho JC, Song M, et al,. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci, 2011; 63: 154-163.
30. Igarashi A, Kato T, Kato M, Song M, Nakagawa H,. The Japanese Ustakinumab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2 â3 clinical trial. J Dermatol, 2012; 39: 242-252.
31. Menter A, Trying SK, Gordon K, et al,. Adalimumab therapy for moderate-to-severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol, 2008; 58: 105-115.
32. Asahina A, Nakagawa H, Etoh T, Ohtsuki M,. Adalimumab in Japanese patients with moderate-to-severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol, 2010; 37: 299-310.
33. Gottlieb AB, Evans R, Li S, et al,. Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol, 2004; 51: 534-542.
34. Reich K, Burden AD, Eaton JN, Hawkins NS,. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol, 2012; 166: 179-88.
35. Menter A, Feldman SR, Weinstein GD, et al,. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol, 2007; 56: 31.e1-31.e15.